Bluejay Diagnostics (BJDX) Common Equity (2020 - 2026)

Bluejay Diagnostics' Common Equity history runs 7 years deep, the most recent figure standing at $4.2 million for Q1 2026.

• In Q1 2026, Common Equity rose 8.14% year-over-year to $4.2 million; the TTM figure through Mar 2026 stood at $4.2 million (up 8.14% YoY), while the FY2025 annual figure was $6.0 million, up 4.29% from the prior year.
• Common Equity came in at $4.2 million for Q1 2026 at Bluejay Diagnostics, down from $6.0 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $18.5 million in Q1 2022 to a low of $2.9 million in Q4 2023.
• A 5-year average of $7.8 million and a median of $6.0 million in 2025 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 13389.68% in 2022 and sank 74.92% in 2023, its largest moves.
• Bluejay Diagnostics' Common Equity stood at $11.5 million in 2022, then tumbled by 74.92% to $2.9 million in 2023, then soared by 97.92% to $5.7 million in 2024, then advanced by 4.29% to $6.0 million in 2025, then sank by 30.03% to $4.2 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $4.2 million, $6.0 million, and $3.7 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison